The much anticipated Local Coverage Determination (LCD) decision has been made in the past 24 hours; Consistent with the proposal, PEB’s Cxbladder tests at this stage will not be covered by CMS on the basis that PEB’s current body of evidence isn’t sufficient to be “considered medically reasonable and necessary”.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.